140 related articles for article (PubMed ID: 35259492)
1. Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment.
Monavarian M; Elhaw AT; Tang PW; Javed Z; Shonibare Z; Scalise CB; Arend R; Jolly MK; Sewell-Loftin MK; Hempel N; Mythreye K
Semin Cancer Biol; 2022 Nov; 86(Pt 2):709-719. PubMed ID: 35259492
[TBL] [Abstract][Full Text] [Related]
2. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer.
Kim S; Kim B; Song YS
Cancer Sci; 2016 Sep; 107(9):1173-8. PubMed ID: 27297561
[TBL] [Abstract][Full Text] [Related]
3. Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.
Gong Y; Yang J; Wang Y; Xue L; Wang J
Int J Cancer; 2020 Oct; 147(7):1768-1777. PubMed ID: 32208517
[TBL] [Abstract][Full Text] [Related]
4. Immune Tumor Microenvironment in Ovarian Cancer Ascites.
Almeida-Nunes DL; Mendes-Frias A; Silvestre R; Dinis-Oliveira RJ; Ricardo S
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142615
[TBL] [Abstract][Full Text] [Related]
5. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
6. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
7. Potential Significance of Peptidome in Human Ovarian Cancer for Patients With Ascites.
Huang X; Zhou J; Tang R; Han S; Zhou X
Int J Gynecol Cancer; 2018 Feb; 28(2):355-362. PubMed ID: 29240604
[TBL] [Abstract][Full Text] [Related]
8. Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer.
Kim S; Han Y; Kim SI; Lee J; Jo H; Wang W; Cho U; Park WY; Rando TA; Dhanasekaran DN; Song YS
Mol Carcinog; 2021 May; 60(5):297-312. PubMed ID: 33721368
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.
Rudlowski C; Pickart AK; Fuhljahn C; Friepoertner T; Schlehe B; Biesterfeld S; Schroeder W
Int J Gynecol Cancer; 2006; 16 Suppl 1():183-9. PubMed ID: 16515588
[TBL] [Abstract][Full Text] [Related]
11. The Epithelial-Mesenchymal Transition Initiated by Malignant Ascites Underlies the Transmesothelial Invasion of Ovarian Cancer Cells.
Pakuła M; Mikuła-Pietrasik J; Witucka A; Kostka-Jeziorny K; Uruski P; Moszyński R; Naumowicz E; Sajdak S; Tykarski A; Książek K
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609691
[TBL] [Abstract][Full Text] [Related]
12. Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer.
Kim S; Lee M; Dhanasekaran DN; Song YS
BMC Cancer; 2018 Dec; 18(1):1232. PubMed ID: 30526541
[TBL] [Abstract][Full Text] [Related]
13. Single-Cell Sequencing of Malignant Ascites Reveals Transcriptomic Remodeling of the Tumor Microenvironment during the Progression of Epithelial Ovarian Cancer.
Li Y; Wang W; Wang D; Zhang L; Wang X; He J; Cao L; Li K; Xie H
Genes (Basel); 2022 Dec; 13(12):. PubMed ID: 36553542
[TBL] [Abstract][Full Text] [Related]
14. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
15. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
16. Expression of FHIT in primary cultures of human epithelial ovarian tumors and malignant ovarian ascites.
Manning AP; Mes-Masson AM; Seymour RJ; Tetrault M; Provencher DM; Tonin PN
Mol Carcinog; 1999 Mar; 24(3):218-25. PubMed ID: 10204806
[TBL] [Abstract][Full Text] [Related]
17. Friend and foe: the regulation network of ascites components in ovarian cancer progression.
Geng Z; Pan X; Xu J; Jia X
J Cell Commun Signal; 2023 Sep; 17(3):391-407. PubMed ID: 36227507
[TBL] [Abstract][Full Text] [Related]
18. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
Bamias A; Koutsoukou V; Terpos E; Tsiatas ML; Liakos C; Tsitsilonis O; Rodolakis A; Voulgaris Z; Vlahos G; Papageorgiou T; Papatheodoridis G; Archimandritis A; Antsaklis A; Dimopoulos MA
Gynecol Oncol; 2008 Feb; 108(2):421-7. PubMed ID: 18036640
[TBL] [Abstract][Full Text] [Related]
19. Spheroid Formation and Peritoneal Metastasis in Ovarian Cancer: The Role of Stromal and Immune Components.
Rakina M; Kazakova A; Villert A; Kolomiets L; Larionova I
Int J Mol Sci; 2022 Jun; 23(11):. PubMed ID: 35682890
[TBL] [Abstract][Full Text] [Related]
20. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
